Michael Dey - Predictive Technology CEO Director
| PRED Stock | USD 0.0001 0.00 0.00% |
CEO
Mr. Michael Dey is Director, Chief Executive Officer of Predictive Therapeutics of the Company. Dr. Dey will assist in corporate governance and guide the development and commercialization of technology and products in all PREDs subsidiaries. In addition to serving as a PRED Board Member, Dr. Dey will continue as Chief Executive Officer of Predicitive Therapeutics, Inc., a wholly owned subsidiary of PRED. Before joining PRED, Dr. Dey had executive positions at Wyeth, later acquired by Pfizer, where he was both the President and the President of Scientific Affairs division for Wyeths Womens Health Care business. As President of Wyeths Womens Health Care business for seven years, Dr. Dey managed its global resources of more than 3 billion annually since 2018.
| Age | 71 |
| Tenure | 7 years |
| Phone | 801 584 3600 |
| Web | https://www.predtechgroup.com |
Predictive Technology Management Efficiency
The company has return on total asset (ROA) of (0.1793) % which means that it has lost $0.1793 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1126) %, meaning that it created substantial loss on money invested by shareholders. Predictive Technology's management efficiency ratios could be used to measure how well Predictive Technology manages its routine affairs as well as how well it operates its assets and liabilities.Predictive Technology Group currently holds 4.47 M in liabilities with Debt to Equity (D/E) ratio of 0.42, which is about average as compared to similar companies. Predictive Technology has a current ratio of 0.28, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Predictive Technology until it has trouble settling it off, either with new capital or with free cash flow. So, Predictive Technology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Predictive Technology sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Predictive to invest in growth at high rates of return. When we think about Predictive Technology's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 10 records | CEO Age | ||
| Douglas Esq | Sarepta Therapeutics | 62 | |
| Andrew MD | Akero Therapeutics | 58 | |
| Stuart Peltz | PTC Therapeutics | 65 | |
| Brian Lian | Viking Therapeutics | 59 | |
| MD FASN | Vertex Pharmaceuticals | 52 | |
| FACS MD | PTC Therapeutics | 52 | |
| Ugur MD | BioNTech SE | 60 | |
| Amy MBA | Terns Pharmaceuticals | 55 | |
| William Sibold | Madrigal Pharmaceuticals | 59 | |
| John Baird | PTC Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.11 | |||
| Return On Asset | -0.18 |
Predictive Technology Leadership Team
Elected by the shareholders, the Predictive Technology's board of directors comprises two types of representatives: Predictive Technology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Predictive. The board's role is to monitor Predictive Technology's management team and ensure that shareholders' interests are well served. Predictive Technology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Predictive Technology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Simon CPA, Consultant | ||
| Bradley Robinson, President CEO, Director | ||
| BS MBA, Chief Officer | ||
| Michael Dey, CEO Director |
Predictive Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Predictive Technology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.11 | |||
| Return On Asset | -0.18 | |||
| Operating Margin | (1.35) % | |||
| Current Valuation | 13.38 M | |||
| Shares Outstanding | 299.6 M | |||
| Price To Earning | (0.11) X | |||
| Price To Book | 0 X | |||
| Price To Sales | 0 X | |||
| Revenue | 24.44 M | |||
| Gross Profit | 3.86 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Predictive Pink Sheet
Predictive Technology financial ratios help investors to determine whether Predictive Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Predictive with respect to the benefits of owning Predictive Technology security.